Ombow, The Glaxo compound is in Phase 1, using healthy volunteers. The Phase 1 writeup indicates they plan to target the cognitive aspects of Schizophrenia. They can run trials, but to eventually commercialize for Schizophrenia they would either have to overturn Cortex's Schizo use patent, or else do a licensing deal with Cortex.
As an indication, the cognitive aspects of Schizophrenia is better suited for a low impact. While the safety aspect of a compound would be less stringent than with something like ADHD, a low impact would still be the way to go both safety-wise, and because neurotrophin upregulation is not a requirement in treating the cognitive aspects of Schizo.
Market Data 
Markets 
AI
